MEENAKSHI ANURAG to Proteogenomics
This is a "connection" page, showing publications MEENAKSHI ANURAG has written about Proteogenomics.
Connection Strength
3.211
-
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell Rep Med. 2025 Jun 17; 6(6):102154.
Score: 0.839
-
How valuable can proteogenomics be in clinical breast cancer research? Expert Rev Proteomics. 2023 Jan-Mar; 20(1-3):1-4.
Score: 0.723
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
Score: 0.701
-
Integrative Proteogenomics and Forward Genetics Reveal a Novel Mitotic Vulnerability in Triple-Negative Breast Cancer. Cancer Discov. 2025 Nov 03; 15(11):2326-2343.
Score: 0.216
-
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
Score: 0.212
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
Score: 0.184
-
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
Score: 0.153
-
Microscaled proteogenomic methods for precision oncology. Nat Commun. 2020 Jan 27; 11(1):532.
Score: 0.145
-
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021 03 08; 39(3):361-379.e16.
Score: 0.039